Unicycive Therapeutics, Inc.

Equities

UNCY

US90466Y1038

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.03 ^USD	+6.19%		-3.74%	+18.70%

Apr. 04	Piper Sandler Initiates Coverage on Unicycive Therapeutics With Overweight Rating, $9 Price Target	MT
Mar. 28	Unicycive Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Unicycive Therapeutics, Inc. announced that it has received $50 million in funding

March 19, 2024

On March 20, 2024, RetinalGenix Technologies Inc. closed the transaction. The transaction included participation from 25 investors. The company paid $3,500,000 as sales commissions in the transaction.

Latest news about Unicycive Therapeutics, Inc.

Piper Sandler Initiates Coverage on Unicycive Therapeutics With Overweight Rating, $9 Price Target	Apr. 04	MT
Unicycive Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Unicycive Therapeutics, Inc. announced that it has received $50 million in funding	Mar. 19	CI
Unicycive Therapeutics, Inc. announced that it expects to receive $50 million in funding	Mar. 13	CI
Unicycive Therapeutics Completes Patient Enrollment in Pivotal Trial for Investigational Therapy for Hyperphosphatemia	Mar. 08	MT
Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate	Mar. 07	CI
Unicycive Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Unicycive Therapeutics Reaches Alignment with the Fda on Path to File New Drug Application for Oxylanthanum Carbonate	23-10-23	CI
Unicycive Therapeutics, Inc. Announces Appointment of Sara Kenkare-Mitra to Board of Directors	23-09-06	CI
HC Wainwright Adjusts Unicycive Therapeutics' Price Target to $4.50 From $7, Keeps Buy Rating	23-08-16	MT
Unicycive Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Unicycive Therapeutics Files Registration Statement on Behalf of Selling Stockholders	23-07-13	MT
Maxim Adjusts Price Target on Unicycive Therapeutics to $4 From $6, Maintains Buy Rating	23-07-03	MT
Roth MKM Adjusts Price Target on Unicycive Therapeutics to $4 From $5, Maintains Buy Rating	23-07-03	MT
Top Midday Decliners	23-06-30	MT
Unicycive Therapeutics' Shares Drop After US FDA Requested Additional Information on Lanthanum Dioxycarbonate Program	23-06-30	MT
Wall Street Set to Open Higher Amid Slowing Inflation; Consumer Sentiment Survey Eyed	23-06-30	MT
Top Premarket Decliners	23-06-30	MT
Unicycive Therapeutics, Inc. Provides Regulatory Update on Lanthanum Dioxycarbonate Program	23-06-30	CI
Unicycive Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-16	CI
Unicycive Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
EF Hutton Starts Unicycive Therapeutics at Buy With $5 Price Target	23-03-09	MT
Maxim Adjusts Price Target on Unicycive Therapeutics to $6 From $3, Maintains Buy Rating	23-03-09	MT
Unicycive Therapeutics to Raise up to $130 Million via Private Placement; Shares Soar	23-03-06	MT
Top Premarket Gainers	23-03-06	MT

Chart Unicycive Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Unicycive Therapeutics, Inc. is a biotechnology company that is developing treatments for certain medical conditions. Its programs are focused on kidney disease, an area that has the potential to offer medical benefits. Its development programs are focused on two novel therapies: Oxylanthanum Carbonate, and UNI 494. Oxylanthanum Carbonate is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. Oxylanthanum Carbonate and UNI 494 were initially developed by and licensed to it from Spectrum Pharmaceuticals (Spectrum) and Sphaera Pharma, respectively.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.03 USD

Average target price

5.3 USD

Spread / Average Target

+414.56%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
UNICYCIVE THERAPEUTICS, INC.	+18.70%	35.8M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research